Zymeworks Stock Price, News & Analysis

Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised its option to continue exclusive rights for the development and commercialization of zanidatamab, following positive clinical data from the HERIZON-BTC-01 trial in biliary tract cancers. The trial showed a 41.3% objective response rate among patients with HER2-amplified disease. Jazz will pay Zymeworks $325 million and may owe up to $1.76 billion in future milestone payments. Zanidatamab aims to provide HER2-targeted therapy for challenging cancers, currently lacking approved treatments.

Zymeworks Inc. (NASDAQ: ZYME) announced positive topline results from its Phase 2b HERIZON-BTC-01 trial of zanidatamab in patients with HER2-amplified biliary tract cancers (BTC). The therapy achieved a confirmed objective response rate of 41.3% and a median duration of response of 12.9 months. Pending regulatory approvals, zanidatamab could become the first HER2-targeted treatment for BTC. The safety profile remained consistent with prior studies, with no new safety signals identified. Full trial results are expected in 2023.

Zymeworks Inc. (NYSE: ZYME) has announced the upcoming presentation of mature Phase 2 data for zanidatamab in combination with chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). This presentation is set to occur at the ASCO Gastrointestinal Cancers Symposium from January 19-21, 2023. The GEA cohort was fully recruited by March 1, 2022, and enrollment for additional cancer cohorts continues. Positive Phase 2 results could support zanidatamab's further development in the Phase 3 HERIZON-GEA-01 study.

Zymeworks Inc. (NYSE: ZYME) presented promising clinical data for zanidatamab at the San Antonio Breast Cancer Symposium. In a study of 45 patients with HER2-positive metastatic breast cancer, the combination treatment of zanidatamab, palbociclib, and fulvestrant achieved a confirmed objective response rate (cORR) of 33% and a disease control rate (DCR) of 92%. The median progression-free survival (mPFS) was reported at 9.6 months. The regimen was generally well-tolerated. These results suggest potential for a chemotherapy-free option for heavily pretreated patients.

Zymeworks Inc. (NYSE: ZYME) announced its decision to transfer its stock listing from the New York Stock Exchange to Nasdaq. The stock will cease trading on NYSE at market close on December 15, 2022, and will begin trading on Nasdaq on December 16, 2022, retaining the ticker symbol ZYME. Zymeworks is focused on developing multifunctional biotherapeutics, with lead candidate zanidatamab undergoing multiple clinical trials for HER2-expressing solid tumors.

Zymeworks Inc. (NYSE: ZYME) has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act regarding its license agreement with Jazz Pharmaceuticals for zanidatamab, a HER2-targeted bispecific antibody. This milestone enables Zymeworks to receive a $50 million non-refundable upfront payment from Jazz, while a potential second payment of $325 million is expected after the readout of clinical data from the HERIZON-BTC-01 study. Zymeworks anticipates sharing the top-line data by the end of 2022.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2023. Management will hold one-on-one meetings and a fireside chat on November 29 at 4:45 pm EST. Presentations and webcasts will be available on Zymeworks’ website. The company focuses on developing multifunctional biotherapeutics, with lead candidate zanidatamab targeting HER2 in clinical trials.

Zymeworks has announced an exclusive licensing agreement with Jazz Pharmaceuticals for zanidatamab, potentially valued at up to $1.76 billion, including a $50 million upfront payment. This quarter showcased promising Phase 1 trial results for zanidatamab zovodotin, demonstrating a 31% objective response rate in HER2-expressing cancers. Zymeworks has transitioned to a Delaware corporate structure to enhance shareholder value and simplify commercialization. The company reported a decreased net loss of $47.8 million for Q3 2022, down 21% from the prior year, and a cash balance of $166.2 million.

Zymeworks (NYSE: ZYME) held its Early R&D Day to showcase advancements in its pipeline and proprietary technology. The company aims to file five new Investigational New Drug applications over the next five years, emphasizing ongoing research in antibody drug conjugates (ADC) and multi-specific antibody therapeutics (MSAT) targeting cancer. Key updates included data on novel ADCs like ZW191 and ZW251, highlighting the potential to address significant patient needs. Zymeworks is committed to developing innovative therapeutics and advancing its R&D initiatives.